Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer | PLOS ONE
![Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients - ScienceDirect Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0009898115003265-t1.jpg)
Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients - ScienceDirect
![Determination of the prognostic value of preoperative CA15‑3 and CEA in predicting the prognosis of young patients with breast cancer Determination of the prognostic value of preoperative CA15‑3 and CEA in predicting the prognosis of young patients with breast cancer](https://www.spandidos-publications.com/article_images/ol/16/4/ol-16-04-4679-g00.jpg)
Determination of the prognostic value of preoperative CA15‑3 and CEA in predicting the prognosis of young patients with breast cancer
![serum Ca 15-3 behavior during postoperative follow-up of patient 2.... | Download Scientific Diagram serum Ca 15-3 behavior during postoperative follow-up of patient 2.... | Download Scientific Diagram](https://www.researchgate.net/publication/329615156/figure/fig2/AS:703368083275776@1544707427023/serum-Ca-15-3-behavior-during-postoperative-follow-up-of-patient-2-Abbreviations-Bs.png)
serum Ca 15-3 behavior during postoperative follow-up of patient 2.... | Download Scientific Diagram
Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer | PLOS ONE
![Paradox CA 15–3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series | Biomarkers in Medicine Paradox CA 15–3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series | Biomarkers in Medicine](https://www.futuremedicine.com/cms/10.2217/bmm-2016-0142/asset/images/medium/figure2.gif)
Paradox CA 15–3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series | Biomarkers in Medicine
![Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment | BMC Cancer | Full Text Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2407-6-81/MediaObjects/12885_2006_Article_433_Fig1_HTML.jpg)
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment | BMC Cancer | Full Text
![Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study | SpringerLink Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12282-020-01058-3/MediaObjects/12282_2020_1058_Fig2_HTML.png)